Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity
<p>Abstract</p> <p>Background</p> <p>in HIV-infected patients with HCV-related chronic hepatitis, liver impairment and drug toxicity may substantially reduce the number of possible therapeutic options.</p> <p>Case Description</p> <p>we here descr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-02-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | http://www.eurjmedres.com/content/15/2/81 |
| _version_ | 1828254872917508096 |
|---|---|
| author | Ortu F Weimer LE Floridia M Manconi PE |
| author_facet | Ortu F Weimer LE Floridia M Manconi PE |
| author_sort | Ortu F |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>in HIV-infected patients with HCV-related chronic hepatitis, liver impairment and drug toxicity may substantially reduce the number of possible therapeutic options.</p> <p>Case Description</p> <p>we here describe the case of an HCV-HIV coinfected woman who had repeated severe episodes of drug-related liver toxicity with indinavir, saquinavir, fosamprenavir, and darunavir, with minimal further therapeutic options left in this class. Previous treatment-limiting side effects with efavirenz and nevirapine also precluded use of non-nucleoside reverse transcriptase inhibitors. Introduction of an integrase-inhibitor regimen based on raltegravir, tenofovir, and emtricitabine allowed a prompt achievement of undetectable viral load and a substantial rise of CD4 count to high levels, with no subsequent episodes of hepatic toxicity, and no other side effects.</p> <p>Conclusions</p> <p>given the relatively common prevalence of HCV-related chronic hepatitis among people with HIV, raltegravir might represent an important alternative option for a substantial number of patients who cannot be treated with protease inhibitors or NNRTI because of drug-related hepatic toxicity.</p> |
| first_indexed | 2024-04-13T02:05:39Z |
| format | Article |
| id | doaj.art-227d48e6d5e74dde846c538330d9dc5e |
| institution | Directory Open Access Journal |
| issn | 2047-783X |
| language | English |
| last_indexed | 2024-04-13T02:05:39Z |
| publishDate | 2010-02-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj.art-227d48e6d5e74dde846c538330d9dc5e2022-12-22T03:07:28ZengBMCEuropean Journal of Medical Research2047-783X2010-02-011528110.1186/2047-783X-15-2-81Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver ToxicityOrtu FWeimer LEFloridia MManconi PE<p>Abstract</p> <p>Background</p> <p>in HIV-infected patients with HCV-related chronic hepatitis, liver impairment and drug toxicity may substantially reduce the number of possible therapeutic options.</p> <p>Case Description</p> <p>we here describe the case of an HCV-HIV coinfected woman who had repeated severe episodes of drug-related liver toxicity with indinavir, saquinavir, fosamprenavir, and darunavir, with minimal further therapeutic options left in this class. Previous treatment-limiting side effects with efavirenz and nevirapine also precluded use of non-nucleoside reverse transcriptase inhibitors. Introduction of an integrase-inhibitor regimen based on raltegravir, tenofovir, and emtricitabine allowed a prompt achievement of undetectable viral load and a substantial rise of CD4 count to high levels, with no subsequent episodes of hepatic toxicity, and no other side effects.</p> <p>Conclusions</p> <p>given the relatively common prevalence of HCV-related chronic hepatitis among people with HIV, raltegravir might represent an important alternative option for a substantial number of patients who cannot be treated with protease inhibitors or NNRTI because of drug-related hepatic toxicity.</p>http://www.eurjmedres.com/content/15/2/81HIV/HCVantiretroviral treatmentraltegravirtenofoviremtricitabinechronic active hepatitis |
| spellingShingle | Ortu F Weimer LE Floridia M Manconi PE Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity European Journal of Medical Research HIV/HCV antiretroviral treatment raltegravir tenofovir emtricitabine chronic active hepatitis |
| title | Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity |
| title_full | Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity |
| title_fullStr | Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity |
| title_full_unstemmed | Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity |
| title_short | Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity |
| title_sort | raltegravir tenofovir and emtricitabine in an hiv infected patient with hcv chronic hepatitis nnrti intolerance and protease inhibitors induced severe liver toxicity |
| topic | HIV/HCV antiretroviral treatment raltegravir tenofovir emtricitabine chronic active hepatitis |
| url | http://www.eurjmedres.com/content/15/2/81 |
| work_keys_str_mv | AT ortuf raltegravirtenofovirandemtricitabineinanhivinfectedpatientwithhcvchronichepatitisnnrtiintoleranceandproteaseinhibitorsinducedseverelivertoxicity AT weimerle raltegravirtenofovirandemtricitabineinanhivinfectedpatientwithhcvchronichepatitisnnrtiintoleranceandproteaseinhibitorsinducedseverelivertoxicity AT floridiam raltegravirtenofovirandemtricitabineinanhivinfectedpatientwithhcvchronichepatitisnnrtiintoleranceandproteaseinhibitorsinducedseverelivertoxicity AT manconipe raltegravirtenofovirandemtricitabineinanhivinfectedpatientwithhcvchronichepatitisnnrtiintoleranceandproteaseinhibitorsinducedseverelivertoxicity |